The Potential Therapeutic Effect of Melatonin in Gastro-Esophageal Reflux Disease

Mansoura University

Status and phase

Withdrawn

Phase 3

Conditions

Gastroesophageal Reflux Disease

Treatments

Drug: Melatonin

Study type

Interventional

Funder types

Other

Identifiers

NCT00915616

Melatonin and reflux

Details and patient eligibility

About

Gastro-Esophageal Reflux Disease was defined as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. Many drugs used for the treatment of GERD such as omeprazole (a proton pump inhibitor) which is widely used anti-ulcer drug and has been demonstrated to protect against esophageal mucosal injury. Melatonin has been found to protect the gastrointestinal mucosa from oxidative damage caused by reactive oxygen species in different experimental ulcer models. The aim of this study is to evaluate the role of exogenous melatonin in the treatment of reflux disease in human either alone and in combination with omeprazole therapy.

Sex

All

Ages

42 to 56 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

patient with GERD ranged from 42 to 56 years

Exclusion criteria

patients with cardiac disease
patients with renal affection
patients with liver diseases (due to drug induced, autoimmune disease and viral hepatitis)
patients on the drugs known to affect the GIT motility (phenothiazines, anticholinergics, nitrates or calcium channel blockers) were excluded during the time of conduction of the study or the preceding two weeks